专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022016165A2 DIFFERENTIATION OF TROPHECTODERM LINEAGE CELLS FROM PLURIPOTENT STEM CELLS 审中-公开
公开(公告)号：WO2022016165A2
公开(公告)日：2022-01-20
申请号：PCT/US2021/070653
申请日：2021-06-02
申请人： THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： SINGEC, Ilyas , SLAMECKA, Jaroslav , SIMEONOV, Anton , DENG, Tao
摘要： Methods for generating in culture of cells resembling mammalian trophectoderm-lineage cells from mammalian pluripotent stem cells are provided, along with the related compositions.

2. 发明申请

WO2019209777A1 IMPROVED CRISPR THERAPY 审中-公开
公开(公告)号：WO2019209777A1
公开(公告)日：2019-10-31
申请号：PCT/US2019/028635
申请日：2019-04-23
申请人： THE CURATORS OF THE UNIVERSITY OF MISSOURI , THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
发明人： DUAN, Dongsheng , HAKIM, Chady , WASALA, Nalinda, B. , YUE, Yongping
IPC分类号： A61K35/76 , A61K48/00 , C12N9/22 , C12N15/113 , C12N15/63 , C12N15/864
摘要： Disclosed herein are methods for systemically editing a gene in a subject and for systemically treating a genetic condition in a subject using a dual -vector CRISPR-Cas therapy. The methods comprise administering to the subject, via systemic administration, a gene editing AAV vector encoding a CRISPR effector protein (e.g., a Cas protein) and a targeting AAV vector providing one or more gRNAs targeted to the gene. In the methods, the ratio of the targeting AAV vector to the gene editing vector is greater than or equal to 2. Also provided are dual -vector systems for editing a gene or treating a genetic disease in a subject.

3. 发明申请

WO2018013855A3 IL-15/IL-15 RECEPTOR ALPHA TREATMENT REGIMENS AND USE WITH THERAPEUTIC VACCINES 审中-公开
标题翻译： IL-15 / IL-15受体α治疗方案及其与治疗性疫苗的应用
公开(公告)号：WO2018013855A3
公开(公告)日：2018-01-18
申请号：PCT/US2017/042002
申请日：2017-07-13
申请人： THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： FELBER, Barbara K. , PAVLAKIS, George N. , VALENTIN, Antonio
IPC分类号： A61K38/20 , G01N33/50 , G01N33/68 , A61K45/06 , A61P31/18 , A61P37/04 , A61P35/00 , A61K9/00 , A61K39/00
摘要： The invention provides dose escalation regimens for administering IL-15/IL-15Ra in a Fibonacci series to a patient suffering from lymphocytopenia, cancer, or an infectious disease. The inventionfurther provides methods for monitoring treatment of a patient with IL-15.
摘要翻译：本发明提供了用于向患有淋巴细胞减少症，癌症或传染病的患者施用Fibonacci系列中的IL-15 / IL-15Ra的剂量递增方案。本发明进一步提供了监测IL-15治疗患者的方法。

4. 发明申请

WO2017040404A1 A METHOD OF DETECTING MOLECULES IN PROXIMITY TO A TARGET MOLECULE IN A SAMPLE 审中-公开
标题翻译：检测样品中目标分子的分子的方法
公开(公告)号：WO2017040404A1
公开(公告)日：2017-03-09
申请号：PCT/US2016/049263
申请日：2016-08-29
申请人： THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： BAR, Daniel Z. , COLLINS, Francis
IPC分类号： G01N33/68
CPC分类号： G01N33/6845
摘要： Antibody-based methods of detecting of molecules interacting with a target molecule, such as a nuclear or cytoplasmic protein, in a fixed and, optionally, permeabilized cell or tissue sample. In one example, the target molecule is bound by a primary antibody, and a secondary, peroxidase-conjugated antibody, then binds to the primary antibody. The peroxidase may also be conjugated the primary antibody. Biotin tyramide is added to the sample, and the peroxidase generates short-lived intermediates resulting in biotinylation of molecules adjacent to the peroxidase. Biotinylated molecules can be isolated from the sample by affinity interaction with avidin- or streptavidin, resulting in a fraction containing biotinylated molecules that are located in the sample in proximity to the target molecule. The fraction can be analyzed by mass-spectroscopy, Western blotting, sequencing and other techniques.
摘要翻译：在固定和任选的透化细胞或组织样品中检测与靶分子例如核或细胞质蛋白相互作用的分子的基于抗体的方法。在一个实例中，靶分子被一级抗体结合，并且次级的，过氧化物酶缀合的抗体然后与一级抗体结合。过氧化物酶也可以与一级抗体结合。将生物素酪胺加入到样品中，过氧化物酶产生短暂的中间体，导致与过氧化物酶相邻的分子的生物素化。生物素化的分子可以通过与抗生物素蛋白或链霉抗生物素蛋白亲和力相互作用从样品中分离出来，导致含有生物素化分子的部分位于样品中靠近靶分子。该分数可以通过质谱，蛋白质印迹，测序和其他技术进行分析。

5. 发明申请

WO2016183420A1 METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE USING CONSERVED ELEMENT CONSTRUCTS 审中-公开
标题翻译：用保护性元素结构诱导免疫应答的方法和组合物
公开(公告)号：WO2016183420A1
公开(公告)日：2016-11-17
申请号：PCT/US2016/032317
申请日：2016-05-13
申请人： THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , UNIVERSITY OF WASHINGTON
发明人： FELBER, Barbara K. , PAVLAKIS, George N. , MULLINS, James I. , VALENTIN, Antonio , MANOCHEEWA, Siriphan
IPC分类号： C07K14/16
CPC分类号： C07K14/161 , A61K2039/53 , A61K2039/545 , A61K2039/572 , C12N2740/16234 , C12N2740/16271
摘要： The invention provides methods and compositions for eliciting broad immune responses to HIV envelope proteins. The methods include use of nucleic acids constructs that encode conserved elements of HIV Env to induce immune responses.
摘要翻译：本发明提供了引发对HIV包膜蛋白的广泛免疫应答的方法和组合物。所述方法包括使用编码HIV Env的保守元件的核酸构建体来诱导免疫应答。

6. 发明申请

WO2016160166A1 IMMUNOGENIC RSV POLYPEPTIDES 审中-公开
标题翻译：免疫原RSV多聚体
公开(公告)号：WO2016160166A1
公开(公告)日：2016-10-06
申请号：PCT/US2016/018530
申请日：2016-02-18
申请人： THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： KHURANA, Surender , GOLDING, Hana
IPC分类号： A61K39/155 , C07K14/135
CPC分类号： A61K39/12 , A61K2039/523 , A61K2039/54 , A61K2039/55 , A61K2039/555 , A61K2039/55566 , A61K2039/645 , A61P31/14 , C12N7/00 , C12N2760/18534 , C12N2760/18571 , G01N33/56983
摘要： This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.
摘要翻译：本发明提供包含免疫兴奋剂和呼吸道合胞病毒（RSV）寡肽或未糖基化的RSV多肽的免疫原性组合物。 RSV寡肽如SEQ ID NO：3-33所示。未糖基化的RSV多肽可以基本上由RSV G蛋白的胞外域组成，如SEQ ID NO：2所示的胞外域或RSV F蛋白的胞外域，如SEQ ID NO：39所示的F蛋白的胞外域。

7. 发明申请

WO2014172661A1 LONE STAR VIRUS 审中-公开
标题翻译：孤星星病毒
公开(公告)号：WO2014172661A1
公开(公告)日：2014-10-23
申请号：PCT/US2014/034684
申请日：2014-04-18
申请人： THE REGENT OF THE UNIVERSITY OF CALIFORNIA , THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： CHIU, Charles , SWEI, Andrea , JOHNSON, Barbara, J.B.
IPC分类号： C12N7/00 , C07K14/175 , C07K16/10 , G01N33/569
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , C07K14/005 , C07K16/10 , C07K2317/24 , C12N2760/12221 , C12N2760/12234 , C12N2760/12251 , C12Q1/701 , G01N33/56983 , G01N2333/175 , G01N2469/10
摘要： This disclosure concerns the isolation, identification and sequencing of a unique Phlebovirus , the Lone Star Virus. Lone Star Virus nucleic acid molecules, proteins and antibodies are disclosed. Methods are also disclosed for the detection, diagnostic and treatment of the Lone Star Virus.
摘要翻译：本公开涉及独特的疫苗病毒，孤星病毒的分离，鉴定和测序。公开了孤星病毒核酸分子，蛋白质和抗体。还公开了用于孤星病毒的检测，诊断和治疗的方法。

8. 发明申请

WO2014150939A2 COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES 审中-公开
标题翻译：疫苗中登革病毒嵌合构建体的组成和方法
公开(公告)号：WO2014150939A2
公开(公告)日：2014-09-25
申请号：PCT/US2014/024603
申请日：2014-03-12
申请人： TAKEDA VACCINES, INC , THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： STINCHCOMB, Dan, T. , HUANG, Claire, Y. , KINNEY, Richard, M. , LIVENGOOD, Jill, A.
IPC分类号： A61K39/12
CPC分类号： A61K38/162 , A61K31/7048 , A61K31/713 , A61K39/12 , A61K2039/5254 , A61K2039/70 , C07K14/005 , C07K14/1825 , C07K19/00 , C12N15/09 , C12N15/8613 , C12N2770/24122 , C12N2770/24134 , C12N2770/24141 , C12N2770/24143 , C12N2770/24162 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要： Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
摘要翻译：这里的实施方案报道了登革热病毒构建体和减毒活登革病毒的组成，用途和制造。一些实施方案涉及包含但不限于四价登革热病毒组合物的组合物。在某些实施方案中，组合物可以包含登革热病毒的一种或多种血清型的构建体，例如登革-1（DEN-1）病毒，登革-2（DEN-2）病毒，登革-3（DEN-3） 4（DEN-4）病毒构建体。在其他实施方案中，本文公开的构建体可以组合在组合物中以产生针对更多的一种或多种登革病毒构建体的疫苗，所述登革病毒构建体可能或可能不会随后在哺乳动物细胞中传代。

9. 发明申请

WO2014059434A1 ASSAY FOR ANALYSES OF RABIES VIRUS GLYCOPROTEIN 审中-公开
标题翻译： RABIES病毒分析蛋白的分析
公开(公告)号：WO2014059434A1
公开(公告)日：2014-04-17
申请号：PCT/US2013/064911
申请日：2013-10-15
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION , SMITH, Todd, Gareth , RUPPRECHT, Charles
发明人： SMITH, Todd, Gareth , RUPPRECHT, Charles
IPC分类号： G01N33/53 , G01N33/563 , C12Q1/70 , G01N33/68
CPC分类号： G01N33/56983 , A61K39/205 , C12N7/00 , C12N2760/20122 , C12N2760/20134 , G01N2333/145 , G01N2333/4728 , G06F19/22
摘要： Provided are processes of determining die immimogenicity of a rabies virus vaccine preparation that for the first tiine correlates well with in vivo results. The methods capitalize on an ECL assay for RABV G protein that is sensitive, reproducible, and can be used to quickly assess characteristics of new vaccine preparations.
摘要翻译：提供了确定狂犬病毒疫苗制剂的死亡不成体的方法，其对于第一阶段与体内结果良好相关。该方法利用敏感，可重复的RABV G蛋白的ECL测定法，可用于快速评估新疫苗制剂的特性。

10. 发明申请

WO2013192144A2 RIFT VALLEY FEVER VIRUS REPLICON PARTICLES AND USE THEREOF 审中-公开
公开(公告)号：WO2013192144A2
公开(公告)日：2013-12-27
申请号：PCT/US2013/046250
申请日：2013-06-18
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： DODD, Kimberly, A. , BIRD, Brian, H. , ALBARINO, Cesar, G. , NICHOL, Stuart, T.
IPC分类号： C12N7/00
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/5258 , C12N7/00 , C12N2760/12223 , C12N2760/12232 , C12N2760/12234 , C12N2760/12251 , C12N2760/12252 , C12N2760/12271 , G01N33/56983 , G01N2469/20 , Y02A50/397
摘要： Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRP RVF ) vaccine candidate. VRP RVF can actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRP RVF immunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRP RVF , methods of producing VRP RVF , and method of using VRP RVF for immunization against RVF virus infection.
摘要翻译：本文公开了用于产生裂谷热（RVF）病毒复制子颗粒（VRPRVF）疫苗候选物的反向遗传学的鲁棒系统。 VRPRVF可以积极合成病毒RNA和蛋白质，但缺乏结构糖蛋白基因，预防免疫个体内的扩散，降低疫苗诱导致病性的风险。本文公开了VRPRVF免疫是安全和有效的，导致在免疫接种24小时内可以有效抵抗RVF病毒攻击的强大的免疫应答。本文提供了VRPRVF，VRPRVF的制备方法以及使用VRPRVF进行RVF病毒感染免疫的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式